Results 231 to 240 of about 25,675 (362)

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout   +22 more
wiley   +1 more source

Essentials of an immunodeficiency primer: A practical reference for the allergist/immunologist and the allergy-immunology fellow-in-training (FIT). [PDF]

Allergy Asthma Proc
Bellanti JA, Settipane RA.
europepmc   +1 more source

How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC

European Journal of Heart Failure, EarlyView.
Linking guideline‐directed medical therapy (GDMT) implementation and appropriate polypharmacy management in heart failure (HF). Polypharmacy can represent a barrier to the proper implementation of life‐prolonging GDMT for HF. A reasonable balance between the optimization of GDMT and avoiding inappropriate polypharmacy is mandatory in the contemporary ...
Davide Stolfo, Massimo Iacoviello, Ovidiu Chioncel, Markus S. Anker, Antoni Bayes‐Genis, Frieder Braunschweig, Antonio Cannata, Seif El Hadidi, Gerasimos Filippatos, Pardeep Jhund, Alexandre Mebazaa, Brenda Moura, Massimo Piepoli, Robin Ray, Arsen D. Ristic, Petar Seferovic, Maggie Simpson, Hadi Skouri, Carlo Gabriele Tocchetti, Sophie Van Linthout, Cristiana Vitale, Maurizio Volterrani, Kalliopi Keramida, Sven Wassmann, Basil S. Lewis, Marco Metra, Giuseppe M.C. Rosano, Gianluigi Savarese   +27 more
wiley   +1 more source

Using T-Cell Subsets to Better Characterize Immunoresiliency and Immunodeficiency in Patients with Recurrent Infections. [PDF]

Infect Dis Rep
Hung J, Vonasek B, Rosenberg D, Vo T, Striker R.   +4 more
europepmc   +1 more source

Recurrent Hospitalisation in a Child With Hypopigmented Hair: Inborn Errors of Immunity Emerge. [PDF]

Cureus
Kundavaram R, Kadiri H, Khurana U, Chaudhary NK, Dhingra B, Bargir U, Malik S.   +6 more
europepmc   +1 more source

Primary Immunodeficiency: Specific antibody deficiency with normal IgG. [PDF]

Allergy Asthma Proc
Hatcher VR, Alix VC, Hellu TS, Schuldt MM.   +3 more
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Unmasking inborn errors of immunity: identifying the red flags of immune dysregulation. [PDF]

Front Immunol
Cortesi M, Dotta L, Cattalini M, Lougaris V, Soresina A, Badolato R.   +5 more
europepmc   +1 more source

Synthetic Biology‐Based Engineering Cells for Drug Delivery

Exploration, EarlyView.
Synthetic biology‐based therapeutic cells for drug delivery: Engineered cells effectively transport and release drugs through their intelligence and controllability, such as feedback pathways and external stimuli (e.g., light and ultrasound). The integration of nanotechnology, including nanoparticles, biofilms, and artificial cells, enhances ...
Wenzhe Yi, Shuangshuang Hu, Xindi Qian, Wenlu Yan, Yaping Li   +4 more
wiley   +1 more source

Inborn Errors of Immunity in Adults with Autoimmune Liver Diseases. [PDF]

Turk J Gastroenterol
Ayar ŞN, Aytekin ES, Şimşek C, Dağ O, Çağdaş D, Balaban YH.   +5 more
europepmc   +1 more source